Ovidrel (choriogonadotropin alfa) / EMD Serono 
Welcome,         Profile    Billing    Logout  
 23 Diseases   10 Trials   10 Trials   138 News 


123»
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    New P1 trial:  A Comparing Study Between SJ04 and Ovidrel (clinicaltrials.gov) -  Sep 20, 2024   
    P1,  N=48, Not yet recruiting, 
  • ||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion date, Trial primary completion date:  Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) -  Nov 3, 2023   
    P1,  N=144, Recruiting, 
    Highly purified human menopausal gonadotropin (HP-hMG [Menopur Trial completion date: May 2024 --> May 2026 | Trial primary completion date: Apr 2024 --> Apr 2026
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Enrollment closed, Trial completion date, Trial primary completion date:  Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) -  Oct 27, 2023   
    P=N/A,  N=80, Active, not recruiting, 
    Trial completion date: May 2024 --> May 2026 | Trial primary completion date: Apr 2024 --> Apr 2026 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
    Trial completion, Phase classification, Trial completion date:  CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) -  May 9, 2023   
    P1/2,  N=200, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025 Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023
  • ||||||||||  progesterone / Generic mfg.
    Trial completion:  Progesterone Levels During Ovulation and Luteal Phase (clinicaltrials.gov) -  Mar 14, 2023   
    P=N/A,  N=6, Completed, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023 Recruiting --> Completed
  • ||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion date, Trial primary completion date:  Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) -  Mar 2, 2023   
    P1,  N=144, Recruiting, 
    Recruiting --> Completed Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion, Trial initiation date, Trial primary completion date:  Can Biotin Supplementation be Used to Mask hCG Abuse? (clinicaltrials.gov) -  Feb 3, 2023   
    P1,  N=10, Completed, 
    Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 Recruiting --> Completed | Initiation date: Jul 2022 --> Oct 2022 | Trial primary completion date: Aug 2022 --> Feb 2023
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Analytical investigation of the profile of human chorionic gonadotropin in highly purified human menopausal gonadotrophin preparations () -  Jan 8, 2023 - Abstract #Fertility2023Fertility_338;    
    Objective: Highly-purified human menopausal gonadotropin (HP-hMG [Menopur, Ferring Pharmaceuticals, Switzerland]) contains 1:1 follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity...The reference was a mixture of r-hFSH/follitropin-alfa (GONAL-f), r-hLH/lutropin alfa [Luveris] and r-hCG (Ovidrel) (Merck KGaA, Darmstadt, Germany) constituted based on their reported activity (in IU) in the HP-hMG product label... Advanced molecular analysis of HP-hMG showed that the relative presence of hCG compared to LH may be higher than in the reference, and revealed absence of sulfated glycans, suggesting a mainly placental origin of hCG, with possible impact on receptor affinity/activation and clinical effect.
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion, Trial completion date, Trial primary completion date:  hCG Priming in Women With Low Ovarian Reserve (clinicaltrials.gov) -  Aug 25, 2022   
    P4,  N=20, Completed, 
    Overall, there was no significant difference in the morphokinetic parameters or quality of embryos evaluated using a time-lapse monitoring system between embryos derived following dual trigger compared with HCG. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2021 | Trial primary completion date: Dec 2022 --> Aug 2021
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
    CAN THE DUAL TRIGGER PROTOCOL IMPACT EMBRYO PLOIDIA? (Anaheim Convention Center - Poster Hall in Expo Hall) -  Aug 21, 2022 - Abstract #ASRM2022ASRM_1125;    
    IMPACT STATEMENT: The results of this study may assist in the selection of patients who may benefit from the dual trigger protocol. In addition, the study will contribute to the development of new studies to better understand the processes of ovulation induction and its effect on embryonic aneuploidies.
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    PREDICTIVE VALUES OF PROGESTERONE/ESTRADIOL RATIO ON INTRAUTERINE INSEMINATION OUTCOMES (Anaheim Convention Center - Poster Hall in Expo Hall) -  Aug 21, 2022 - Abstract #ASRM2022ASRM_692;    
    Further studies, including different stimulation protocols and patients with different infertility diagnoses, are needed in order to confirm the effect of the P/E2 ratio. IMPACT STATEMENT: Based on the obtained results in the presented research, P/E2 ratio measured seven days after intrauterine insemination can be utilized as one of the clinical tests to predict the occurrence of clinical pregnancies.
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono, NN1213 / Novo Nordisk
    Trial completion:  IVF Treatment in Women With Immature Oocytes in Previous Cycle (clinicaltrials.gov) -  Jun 24, 2022   
    P=N/A,  N=100, Completed, 
    IMPACT STATEMENT: Based on the obtained results in the presented research, P/E2 ratio measured seven days after intrauterine insemination can be utilized as one of the clinical tests to predict the occurrence of clinical pregnancies. Unknown status --> Completed
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion:  AMJH: Follicle Size and Oocyte Development (clinicaltrials.gov) -  Jun 24, 2022   
    P=N/A,  N=200, Completed, 
    Unknown status --> Completed Unknown status --> Completed
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Enrollment closed, Trial primary completion date:  hCG Priming in Women With Low Ovarian Reserve (clinicaltrials.gov) -  May 6, 2022   
    P4,  N=20, Active, not recruiting, 
    Unknown status --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Journal:  Identification and semi-relative quantification of intact glycoforms of human chorionic gonadotropin alpha and beta subunits by nano liquid chromatography-Orbitrap mass spectrometry. (Pubmed Central) -  Mar 17, 2021   
    A method based on the analysis of hCG glycoforms at the intact level by nano-reversed phase liquid chromatography coupled to high resolution mass spectrometry (nanoLC-HRMS) with an Orbitrap analyzer was previously developed using a recombinant hCG-based drug, Ovitrelle®, as standard...The RSDs of the relative peak area measured on the extracted ion chromatogram of each glycoform were below 20% (n = 3), with an average value of 9.8%, thus allowing semi-relative quantification. Therefore, this method has a high potential for rapid quality control aiming for the detection and comparison of glycoforms present in glycoprotein-based pharmaceutical preparations.
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
    Enrollment closed, Trial completion date:  CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) -  Feb 23, 2021   
    P=N/A,  N=200, Active, not recruiting, 
    Therefore, this method has a high potential for rapid quality control aiming for the detection and comparison of glycoforms present in glycoprotein-based pharmaceutical preparations. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Enrollment open:  hCG Priming in Women With Low Ovarian Reserve (clinicaltrials.gov) -  Jan 28, 2021   
    P4,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    New P4 trial:  hCG Priming in Women With Low Ovarian Reserve (clinicaltrials.gov) -  Nov 24, 2020   
    P4,  N=20, Not yet recruiting, 
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion date, Trial primary completion date:  Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) -  Nov 19, 2020   
    P=N/A,  N=80, Recruiting, 
    December 15, 2016. Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
  • ||||||||||  estradiol valerate / Generic mfg.
    Trial completion date, Trial primary completion date:  Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient (clinicaltrials.gov) -  Sep 24, 2020   
    P=N/A,  N=450, Recruiting, 
    Premature ovulation or luteinization in modified natural IVF cycles can be avoided without any adverse effect on IVF outcome by early injection of hCG in infertile patients with AMA over 40. Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Jun 2021
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion date, Trial primary completion date:  AMJH: Follicle Size and Oocyte Development (clinicaltrials.gov) -  Apr 8, 2020   
    P=N/A,  N=200, Recruiting, 
    Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Jun 2021 Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
  • ||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion date, Trial primary completion date:  Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) -  Mar 10, 2020   
    P1,  N=144, Recruiting, 
    Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Dec 2023
  • ||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
    Enrollment open:  Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) -  Sep 4, 2019   
    P1,  N=144, Recruiting, 
    Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial primary completion date:  Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) -  Aug 30, 2019   
    P=N/A,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Dec 2018 --> Dec 2019